Overview

A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Status:
RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of OLX72021 in medically healthy men with mild to moderate androgenetic alopecia.
Phase:
PHASE1
Details
Lead Sponsor:
Olix Pharmaceuticals, Inc.
Collaborator:
Avance Clinical Pty Ltd.